-
1
-
-
0028874048
-
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
-
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
-
(1995)
Nature
, vol.373
, pp. 123-126
-
-
Ho, D.D.1
Neumann, A.U.2
Perelson, A.S.3
Chen, W.4
Leonard, J.M.5
Markowitz, M.6
-
2
-
-
0028811974
-
Viral dynamics in human immunodeficiency virus type 1 infection
-
Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-22.
-
(1995)
Nature
, vol.373
, pp. 117-122
-
-
Wei, X.1
Ghosh, S.K.2
Taylor, M.E.3
-
3
-
-
0030952479
-
Decay characteristics of HIV-1-infected compartments during combination therapy
-
Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
-
(1997)
Nature
, vol.387
, pp. 188-191
-
-
Perelson, A.S.1
Essunger, P.2
Cao, Y.3
-
4
-
-
0033984045
-
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
-
Ramratnam B, Mittler J, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6:82-5.
-
(2000)
Nat Med
, vol.6
, pp. 82-85
-
-
Ramratnam, B.1
Mittler, J.2
Zhang, L.3
-
5
-
-
0032953920
-
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
-
Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-25.
-
(1999)
Nat Med
, vol.5
, pp. 512-525
-
-
Finzi, D.1
Blankson, J.2
Siliciano, J.D.3
-
6
-
-
41649083599
-
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
-
Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-84.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 3879-3884
-
-
Palmer, S.1
Maldarelli, F.2
Wiegand, A.3
-
7
-
-
0038579210
-
Long term follow-up studies confirm the extraordinary stability of the latent reservoir for HIV-1 in resting CD4+ T cells
-
Siliciano JD, Kajdas J, Finzi D, et al. Long term follow-up studies confirm the extraordinary stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Med 2003; 9:727-8.
-
(2003)
Nature Med
, vol.9
, pp. 727-728
-
-
Siliciano, J.D.1
Kajdas, J.2
Finzi, D.3
-
8
-
-
0034723439
-
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
-
Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-50.
-
(2000)
Science
, vol.287
, pp. 646-650
-
-
Hazuda, D.J.1
Felock, P.2
Witmer, M.3
-
9
-
-
69449101785
-
Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial
-
Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
-
(2009)
Lancet
, vol.374
, pp. 796-806
-
-
Lennox, J.L.1
Dejesus, E.2
Lazzarin, A.3
-
10
-
-
37349120701
-
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
-
Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-21.
-
(2007)
AIDS
, vol.21
, pp. 2315-2321
-
-
Murray, J.M.1
Emery, S.2
Kelleher, A.D.3
-
11
-
-
42449150053
-
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle
-
Sedaghat AR, Dinoso JB, Shen L, et al. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA2008;105:4832-7.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 4832-4837
-
-
Sedaghat, A.R.1
Dinoso, J.B.2
Shen, L.3
-
12
-
-
0037199389
-
Modeling HIV viral rebound using non-linear mixed effects models
-
Fitzgerald AP, DeGruttola VG, Vaida F. Modeling HIV viral rebound using non-linear mixed effects models. Stat Med 2002; 21:2093-108.
-
(2002)
Stat Med
, vol.21
, pp. 2093-2108
-
-
Fitzgerald, A.P.1
Degruttola, V.G.2
Vaida, F.3
-
13
-
-
34047224560
-
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
-
Kuritzkes DR, Ribaudo HJ, Squires KE, et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis 2007; 195:1169-76.
-
(2007)
J Infect Dis
, vol.195
, pp. 1169-1176
-
-
Kuritzkes, D.R.1
Ribaudo, H.J.2
Squires, K.E.3
-
14
-
-
80855132700
-
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
-
Haubrich RH, Riddler SA, Ribaudo H, et al. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS 2001; 25:2269-78.
-
(2001)
AIDS
, vol.25
, pp. 2269-2278
-
-
Haubrich, R.H.1
Riddler, S.A.2
Ribaudo, H.3
-
15
-
-
77957900795
-
Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
-
Jochmans D, Anders M, Keuleers I, et al. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease. Retrovirology 2010; 7:89.
-
(2010)
Retrovirology
, vol.7
, pp. 89
-
-
Jochmans, D.1
Anders, M.2
Keuleers, I.3
-
16
-
-
77956856393
-
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial
-
pii
-
Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:pii: e1000321.
-
(2010)
PLoS Med
, vol.7
-
-
Gandhi, R.T.1
Zheng, L.2
Bosch, R.J.3
-
17
-
-
67249121143
-
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
-
Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009; 106:9403-8.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 9403-9408
-
-
Dinoso, J.B.1
Kim, S.Y.2
Wiegand, A.M.3
-
18
-
-
79953000877
-
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response
-
Dahl V, Sinclair E, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960-8.
-
(2011)
J Infect Dis
, vol.203
, pp. 960-968
-
-
Dahl, V.1
Sinclair, E.2
-
19
-
-
33845366857
-
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatmentnaive HIV-1-infected individuals
-
Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatmentnaive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-15.
-
(2006)
J Acquir Immune Defic Syndr
, vol.43
, pp. 509-515
-
-
Markowitz, M.1
Morales-Ramirez, J.O.2
Nguyen, B.Y.3
-
20
-
-
34748860363
-
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study
-
Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-33.
-
(2007)
J Acquir Immune Defic Syndr
, vol.46
, pp. 125-133
-
-
Markowitz, M.1
Nguyen, B.Y.2
Gotuzzo, E.3
-
21
-
-
0029967721
-
HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
-
Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.
-
(1996)
Science
, vol.271
, pp. 1582-1586
-
-
Perelson, A.S.1
Neumann, A.U.2
Markowitz, M.3
|